Exagen Inc

XGN03 Dec 2024
Healthcare
$4.05
+0.04 (+4.28%)
Lowest Today
$3.91
Highest Today
$4.12
Today’s Open
$4.05
Prev. Close
$3.97
52 Week High
$4.83
52 Week Low
$1.3
To Invest in Exagen Inc

Exagen Inc

Healthcare
XGN03 Dec 2024
+0.04 (+4.28%)
1M
3M
6M
1Y
5Y
Low
$3.91
Day’s Range
High
$4.12
3.91
52 Week Low
$1.3
52-Week Range
52 Week High
$4.83
1.3
1 Day
-
1 Week
+2.07%
1 month return
+59.73%
3 month return
+37.66%
6 month return
+111.36%
1 Year return
+131.21%
3 Years return
-59.28%
5 Years return
-76.52%
10 Years return
-
Institutional Holdings
RTW INVESTMENTS, LLC
8.63
Morgan Stanley - Brokerage Accounts
5.51
COWEN AND COMPANY, LLC
5.09
Silvercrest Asset Management Group LLC
3.11
Vanguard Group Inc
2.8
Wasatch Advisors LP
2.8
Perkins Capital Management Inc
2.62

Market Status

Fundamentals
Market Cap
67.73 mln
PB Ratio
5.26
PE Ratio
0
Enterprise Value
69.25 mln
Total Assets
56.94 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Organisation
Exagen Inc
Employees
174
Industry
Diagnostics & Research
CEO
Mr. John  Aballi
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step